TFF Pharmaceuticals (NASDAQ:TFFP) Stock, Quote.Headers.trade-ideas

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ARRY

BLUE

CVAC

IVVD

LYFT

QURE

SFWL

TFFP

VTNR

U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday.

Shares of bluebird bio, Inc.  (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company announced a proposed public offering of $150 million of common stock.

Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday

AAMC

AKTX

AREN

CALT

CELL

CLEU

CSSE

DCTH

DSGN

EAST

FTCH

FWAC

FXLV

GETY

GLTO

GMVD

GROV

HCTI

HRYU

IONM

MGOL

NDRA

NOGN

NVOS

ONON

OPRX

PBTS

PHVS

PSFE

PTRA

RGTI

SLGC

SYTA

TAYD

TBLT

TCRT

TLSA

TRKA

TSVT

TTOO

TWOU

WLDS

XWEL

Gainers


	Novo Integrated Sciences, Inc.  (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project.


Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

APVO

JTAI

SONM

TSHA

Gainers


	Delcath Systems, Inc. (NASDAQ: DCTH) shares surged 57.7% to $4.93 in pre-market trading after the company reported the FDA approval of HEPZATO KIT™ for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.


Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket

TFF Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

RPTX

HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target

The cryptocurrency market has seen a significant surge in pre-market activity after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reached a new high of $63,500.
What Happened: Following Bitcoin&#8217;s 0.4% increase, several Bitcoin ETFs experienced a surge in pre-market activity on Monday. As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, Grayscale Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>) rose by 1.46%, Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>) by 1.31%, and ProShares Bitcoin Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITO#NYSE">BITO</a>) by 1.21%. Other ETFs, including Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>) and ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), also witnessed minor increases of 0.99% and 0.77%, respectively. 
Reuters reported that Chris Weston, head of research at Pepperstone, attributed the surge to the &#8220;goldilocks macro backdrop,&#8221; which he believes is the primary driver of the current upward momentum. He also noted that Bitcoin&#8217;s rallies tend to be powerful, sparking significant FOMO (fear of missing out) among crypto investors.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40968244/trumps-new-crypto-ventures-legal-counsel-accused-of-attempting-to-seize-control-of-rival-f?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s New Crypto Venture&#8217;s Legal Counsel Accused Of Attempting To Seize Control Of Rival Firm</a>
Why It Matters: This surge in Bitcoin ETFs comes on the heels of a recent report by 10x Research, which suggested that <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40955750/bitcoins-correction-ends-but-it-has-to-break-this-target-to-surge-to-70k-10x-research">Bitcoin&#8217;s correction phase </a>may have ended. The report indicated a potential surge towards the $70,000 mark, with trading signals showing a favorable buying opportunity for Bitcoin and Ethereum.
Earlier in September, a viral story <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40946963/bitcoin-worth-63-000-pulled-in-33-pack-of-trading-cards-at-gamestop-mind-boggling-story-go">about a GameStop customer</a> who turned a $33 trading card pack into a full Bitcoin worth over $60,000 also highlighted the growing influence of cryptocurrency in mainstream markets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40972902/kamala-harris-finally-mentions-crypto-and-that-too-on-wall-street-promises-to-encourage-in?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kamala Harris Finally Mentions Crypto And That Too On Wall Street: Promises To Encourage &#8216;Innovative Technologies&#8217; Like Digital Assets</a></li>
</ul>
Photo courtesy: Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

General

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

BITO

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

Bitcoin ETF Surge In Pre-Market As King Crypto Hits $63,500

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $60 price target.

DKNG

Needham Reiterates Buy on DraftKings, Maintains $60 Price Target

TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) inked a deal to supply Air France-KLM with up to 1.5 million tons of sustainable aviation fuel (SAF) over the next 10 years, through 2035.
This is one of Air France-KLM&#8217;s largest SAF agreements. This contract builds on a 2022 memorandum of understanding (MoU) for the supply of 800,000 tons of SAF.
By revisiting the agreement, both groups are reinforcing their commitment to reducing the environmental impact of air transport and lowering CO2 emissions as quickly as possible.
Patrick Pouyanné, Chairman and CEO of TotalEnergies, said, &#8220;SAF contributes both to the energy transition of our customers in the aviation sector and to the industrial transition of our refineries. It therefore represents a real &#8216;win-win&#8217; for the future of industry and aviation.&#8221;
&#8220;Securing the volumes of more sustainable aviation fuel needed to decarbonize our activity is a major challenge. This agreement with TotalEnergies is a further step in this direction, and a testament to our long-standing support for the development of SAF production in France and Europe,&#8221; said&nbsp;Benjamin Smith, Chief Executive Officer of Air France-KLM Group.
Notably, TotalEnergies has invested 340 million euros to convert its refinery into a biorefinery. In 2024, the company invested an additional 70 million euros to process up to 100% of waste from the circular economy, with plans to produce sustainable aviation fuel (SAF) by 2025.
Last week, TotalEnergies extended its sales and purchase agreement (SPA) with CNOOC <a target="_blank" href="https://www.benzinga.com//node/40934542" rel="noreferrer noopener">by an additional five years</a>.
Also, the company inked a 10-year deal with BOTAŞ to supply 1.1 million tons of <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40919924/totalenergies-expands-in-turkey-with-long-term-lng-agreement" rel="noreferrer noopener">LNG annually starting in 2027.</a>
Apart from this, this month, the company formed a 50/50 joint venture with Adani Green for a 1,150 MW solar project in Gujarat, India. TotalEnergies will invest $444 million,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40681721/totalenergies-invests-in-indian-solar-projects-forms-jv-with-adani-green-energy" rel="noreferrer noopener">boosting its renewable energy strategy</a>.
Investors can gain exposure to the stock via&nbsp;Advisor Managed Portfolios Miller Value Partners Appreciation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MVPA#NYSE">MVPA</a>) and&nbsp;Octane All-Cap Value Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTA#NASDAQ">OCTA</a>).
Price Action: TTE shares closed lower by 0.07% at $69.09 on Friday.

Equities

Contracts

MVPA

OCTA

TotalEnergies And Air France-KLM Double Down On Sustainability: SAF Deal Paves The Way To Carbon-Free Skies

Needham analyst Bernie McTernan initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $270.

Initiation

FLUT

Needham Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $270

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and maintains $80 price target.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target

TD Cowen analyst Andrew Charles reiterates McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Hold and maintains $280 price target.

TD Cowen Reiterates Hold on McDonald's, Maintains $280 Price Target

Fortis Inc. ("Fortis" or the "Corporation") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTS#NYSE">FTS</a>) announced today that its wholly owned subsidiary Fortis&nbsp;Energy Caribbean Inc. ("FECI") has agreed to provide a standby commitment (the "Standby Commitment") for a rights offering (the&nbsp;"Rights&nbsp;Offering") by Caribbean Utilities Company, Ltd. ("CUC") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CUP#TSX">CUP</a>). Pursuant to the Rights Offering, CUC&nbsp;will issue up to an aggregate of 3,822,298 or 10% of its currently issued and outstanding Class&nbsp;A Ordinary Shares (the "CUC Shares"). FECI will exercise the rights issued to it in the Rights Offering and will acquire a minimum of 2,220,422 CUC Shares at a price of US$13.41 per CUC Share for aggregate consideration of US$29,775,859.02. &nbsp;
Subject to certain customary terms and conditions, FECI may acquire up to 1,601,876 additional CUC Shares at the same price pursuant to the Standby Commitment. If there are no other subscribers in the Rights Offering, FECI will acquire a total of 3,822,298 CUC Shares through the Rights Offering and Standby Commitment for aggregate consideration of US$51,257,016.18. Based on the average daily rate of exchange quoted by the Bank of Canada on September 19, 2024, the consideration in Canadian dollars is C$18.19 per CUC Share or aggregate consideration of C$69,527,600.62 should there be no other subscribers in the Rights Offering.
Prior to the Rights Offering, Fortis indirectly owned 22,204,229 CUC Shares representing approximately 58% of the CUC Shares. On closing of the Rights Offering, which is expected to occur on or about November 4, 2024, Fortis will beneficially own approximately 58% of the CUC Shares if the Rights Offering is fully subscribed or approximately 62% of the CUC Shares if there are no other subscribers in the Rights Offering.
The purpose of the Rights Offering is to provide CUC with capital to be used to finance alternative energy projects, ongoing additions and upgrades to its generation, transmission and distribution systems and for general corporate purposes.
Fortis will review its holdings in CUC Shares from time to time and may acquire additional securities or dispose of securities of CUC, in either case, in the open market, by private agreement or otherwise, depending on numerous factors, including without limitation, the availability of securities of CUC, economic conditions, market conditions and other business and investment opportunities available to Fortis.

TSX:CUP

Fortis Subsidiary Commits $51M in Standby for Caribbean Utilities Rights Offering, Boosts Stake to 62%

As a result of the lifting of the stop work order, the Company will proceed with fulfilling the $128 million delivery order issued under the contract.
The lifting of the stop work order does not affect the U.S. Government Accountability Office&rsquo;s consideration of the protest filed earlier this month challenging the award of the contract to the Company.

AVAV

US Army Lifts Stop Work Order It Issued On Contract With Ceiling Value Of $990M With AeroVironment Related To Switchblade Systems - Filing

Andy &amp; Evan, a renowned children's apparel brand, is delighted to announce a special partnership with Paramount Consumer Products to unveil an extraordinary collaboration featuring Nickelodeon's beloved character, SpongeBob SquarePants. The exclusive SpongeBob SquarePants x Andy &amp; Evan collection is set to launch on September 26th, 2024, celebrating the series' 25th anniversary year.
SpongeBob SquarePants, with his infectious positivity and adventurous spirit, has captured the hearts of audiences worldwide. This unique collaboration with Andy &amp; Evan aims to bring the whimsical world of Bikini Bottom to life through a vibrant and stylish apparel line for children. The collection will cater to boys and girls, available in sizes ranging from infant to 14, and will include a variety of clothing and accessories such as outerwear, tees, hoodies, dresses, and collectible bombers.
The timing of this collaboration aligns with Nickelodeon's celebration of SpongeBob SquarePants' 25th anniversary, a year-long extravaganza honoring the iconic character and his enduring impact on pop culture. The SpongeBob x Andy &amp; Evan collection is a fantastic addition to the celebratory events and merchandise commemorating this milestone anniversary.

PARA

Andy & Evan Partner with Paramount Consumer Products, Launch SpongeBob SquarePants Collection for 25th Anniversary

Wyoming&nbsp;assets&nbsp;comprise&nbsp;of the wholly-owned and fully-licensed Sweetwater Plant &nbsp;and a portfolio of uranium mining projects with approximately 175 million pounds of historic resources.
Completion of the Transaction is subject to customary conditions for a transaction of this nature, with closing expected to occur in the&nbsp;fourth quarter&nbsp;of the calendar year 2024.&nbsp;

Uranium Energy Enters Agreement To Acquire 100% Of Rio Tinto's Wyoming Assets; Purchase Price Payable At Closing Is $175M

Biotech

Health Care

IDYA

Ideaya Biosciences Announced Interim Phase 2 Trial Data For Darovasertib In Neoadjuvant Uveal Melanoma And A Successful Fda Type C Meeting On Registrational Trial Design For Regulatory Approval

STSS

Sharps Technology Enters Definitive Deals With Institutional Investors For Secured Bridge Loan Financing Of Approx. $3.5M

Guggenheim analyst Vamil Divan initiates coverage on Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy rating and announces Price Target of $96.

KROS

Guggenheim Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target of $96

Bernstein analyst Adrian Yanoshik downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Outperform to Market Perform and announces $53 price target.

Downgrades

Bernstein Downgrades General Motors to Market Perform, Announces $53 Price Target

TD Cowen analyst Andrew Charles maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Buy and raises the price target from $115 to $130.

CAVA

TD Cowen Maintains Buy on Cava Group, Raises Price Target to $130

Shares of Granite Point Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) rose sharply in today's pre-market trading after the company announced a third-quarter common and p<a href="https://www.benzinga.com/quote/GPMT/news">referred stock dividends</a>.
After the market close on Friday, Granite Point Mortgage Trust declared a quarterly cash dividend of 5 cents per share of common stock for the third quarter of 2024. The company's board also declared a quarterly cash dividend of 43.75 cents per share of the 7.00% Series A Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock.
Granite Point Mortgage Trust shares gained 3.2% to $2.93 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 73.3% to $0.3683 in pre-market trading after gaining over 5% on Friday.</li>
<li>Linkage Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) gained 54.1% to $0.6445 in the pre-market trading session after dipping 57% on Friday.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) rose 42.9% to $19.99 in pre-market trading after dipping more than 25% on Friday.</li>
<li>Nuvve Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares rose 30.9% to $5.13 in pre-market trading after tumbling over 16% on Friday.</li>
<li>Garden Stage Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) gained 26.7% to $1.70 in pre-market trading after dipping 83% on Friday.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 23.5% to $0.84 in pre-market trading.</li>
<li>Gogoro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) gained 16.4% to $0.60 in pre-market trading after falling 13% on Friday.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) rose 12.8% to $0.4006 in pre-market trading after dipping 12% on Friday. Stem recently named David Buzby as interim CEO following John Carrington&#8217;s departure.</li>
<li>AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) shares gained 7.1% to $3.95 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) fell 21.5% to $3.20 in pre-market trading after jumping around 55% on Friday.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares fell 21.1% to $0.6080 in pre-market trading. The company recently announced findings regarding the compatibility of sutures in human clinical trials of PRF-110.</li>
<li>SolarMax Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) shares dipped 19.7% to $0.70 in pre-market trading after surging 9% on Friday.</li>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) fell 19% to $0.31 in pre-market trading following a 4% decline on Friday.</li>
<li>Chijet Motor Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares declined 18.5% to $2.28 in pre-market trading. Chijet Motor Company announced issuance of ordinary shares to holders of contingent value rights.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) fell 16% to $0.10 in today's pre-market trading after jumping 37% on Thursday.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) shares declined 15.2% to $2.05 in pre-market trading. Gaxos.ai announced exercise of warrants for $3.24 million gross proceeds.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 14.8% to $0.0780 in pre-market trading after the company received Nasdaq delisting notification.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares fell 10.3% to $15.00 in pre-market trading after gaining more than 5% on Friday.</li>
<li>James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares fell 6% to $39.49 in pre-market trading after gaining more than 8% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

ACIU

ADTX

CERO

CJET

GPMT

GSIW

GXAI

LGCB

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

NUKK

NVVE

PGHL

PRFX

SMXT

STEM

WHLR

ZJYL

Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

After weeks of uncertainty, Democratic presidential hopeful Kamala Harris finally put her cryptocurrency cards on the table, eliciting mixed reactions from industry observers.
What happened: At a fundraising event at Wall Street, the vice president<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40972902/kamala-harris-finally-mentions-crypto-and-that-too-on-wall-street-promises-to-encourage-in"> vowed to protect</a> the interests of emerging technologies like artificial intelligence and digital assets.
Harris' first-ever public mention of cryptocurrencies on the campaign trail got enthusiasts excited, especially the ones favoring her in the election
Anthony Scaramucci, CEO of investment firm SkyBridge Capital, said, "Kamala means Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) in every language."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Kamala means Bitcoin in every language
&mdash; Anthony Scaramucci (@Scaramucci) <a href="https://twitter.com/Scaramucci/status/1838016216645914765?ref_src=twsrc%5Etfw">September 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another prominent market observer and founder of venture fund Cinneamhain Ventures, Adam Cochran, said Harris proved naysayers wrong with her "pro-digital assets" remark.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440; Progress moves slowly But it does move. There is your first formal statement, directly from Harris that is reasonably pro-digital assets. Proving that the naysayers who thought it not being in her platform was some evil plan, had no idea what they were talking about &#x1f937;&#x200d;&#x2642;&#xfe0f;… <a href="https://t.co/ynldI6RBtK">https://t.co/ynldI6RBtK</a>
&mdash; Adam Cochran (adamscochran.eth) (@adamscochran) <a href="https://twitter.com/adamscochran/status/1837972999045046618?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
That said, neutral observers also welcomed Harris' crypto-friendly remark. Coinbase's Chief Policy Officer Faryar Shirzad dubbed the statement "important and constructive."
"We should press for more, but her statement today means a lot and we should recognize that," the executive noted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is an important and constructive statement from <a href="https://twitter.com/KamalaHarris?ref_src=twsrc%5Etfw">@KamalaHarris</a>. It's not nearly as forward leaning as the concrete and visionary positions taken by <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a>, but it's still notable because: &#8211; she recognizes digital asset innovation as being important and on par… <a href="https://t.co/sIzq06a4lU">https://t.co/sIzq06a4lU</a>
&mdash; Faryar Shirzad &#x1f6e1;&#xFE0F; (@faryarshirzad) <a href="https://twitter.com/faryarshirzad/status/1837967033612546429?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Jake Chervinsky, Chief Legal Officer at Variant Fund, said, "This is progress and progress is good," although he wanted to know more about her policy.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is progress and progress is good… …but "while protecting our consumers and investors" could mean a lot of things. The anti-crypto army uses "consumer protection" as a smoke screen to conceal their attempts to destroy our industry. I, for one, want to see policy details. <a href="https://t.co/Zc1aUdOYzl">https://t.co/Zc1aUdOYzl</a>
&mdash; Jake Chervinsky (@jchervinsky) <a href="https://twitter.com/jchervinsky/status/1838000616829862216?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40950912/bitcoins-reserve-asset-appeal-increased-due-to-state-of-us-federal-deficit-and-debt-says-b">Bitcoin&#8217;s Reserve Asset Appeal Increased Due To State Of US Federal Deficit And Debt, Says BlackRock: A Hedge Against &#8216;Possible Future Events&#8217; Affecting The Dollar</a>
However, not everyone was convinced. Pierre Rochard, VP of Research at Riot Platforms, said that Harris was "fully aligned" with anti-cryptocurrency crusader Senator Elizabeth Warren (D-Mass.) on pushing central bank digital currencies and shadow-banning Bitcoin.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Kamala is fully aligned with Elizabeth Warren on pushing a CBDC and shadow-banning Bitcoin, read between the lines here <a href="https://t.co/6elzRi12ht">https://t.co/6elzRi12ht</a>
&mdash; Pierre Rochard (@BitcoinPierre) <a href="https://twitter.com/BitcoinPierre/status/1837964639596171649?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Additionally, Ryan Selkis, the founder of on-chain analytics firm Messari, also known for his pro-Trump statements, outrightly dismissed Harris' overture.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If you believe this, you deserve to work on Wall Street on a soulless CBDC desk. <a href="https://t.co/ezpS6IvPyk">https://t.co/ezpS6IvPyk</a>
&mdash; Ryan Selkis (d/acc) &#x1f1fa;&#x1f1f8; (@twobitidiot) <a href="https://twitter.com/twobitidiot/status/1837948219684233651?ref_src=twsrc%5Etfw">September 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Bitcoin rallied sharply since Harris&#8217; remarks, climbing as high as $64,660 before relinquishing gains to trade at $63,539.22 as of this writing, according to&nbsp;<a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo created using Shutterstock and Midjourney.

Politics

$SOL

Kamala Harris' First Public Mention Of Cryptocurrencies On Campaign Trail Sparks Excitement Among Enthusiasts: 'This Is Progress And Progress Is Good…'

Small Cap Consumer Research analyst Eric Beder maintains Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) with a Buy and raises the price target from $24 to $30.

JAKK

Small Cap Consumer Research Maintains Buy on Jakks Pacific, Raises Price Target to $30

XOMA Royalty Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: &nbsp;
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shall receive a cash dividend equal to $0.53906 per share.&nbsp;&nbsp;
Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAO#NASDAQ">XOMAO</a>), shall receive a cash dividend equal to $0.52344 per depositary share.&nbsp;&nbsp;
The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024.&nbsp;&nbsp;

Dividends

XOMA

XOMAO

XOMAP

XOMA Announces $0.53906 for Series A, $0.52344 for Series B Preferred Dividends, Record Date October 3

The latest announcement is out from TFF Pharmaceuticals (TFFP). On April 29, 2024, TFF Pharmaceuticals shared an enlightening scientific presentati...

TFF Pharmaceuticals Signals Advancements in Investor Update

TFF Pharmaceuticals announces pricing of $4.8M public offering

TFF Pharmaceuticals GAAP EPS of -$2.40, revenue of $203.27M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the first quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$2.40. This was below the analyst estimate for EPS of -$2.26.</li><li>The company reported revenue of $203,273.</li><li>This was 190.39% better than the analyst estimate for revenue of $70,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tffp-stock-earnings-tff-pharmaceuticals-for-q1-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;



Bottom-picking is risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to mitigate those risks.&nbsp;



For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;



This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. 



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a>The growing demand for EVs has spotlighted companies like Microvast Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;



The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;



Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;



In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;



TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.



A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.



Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.



But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div>Formerly known as Knowledgetree Ventures, My Size (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/">MYSZ</a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;



While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;



My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;



Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;



On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the second quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

MVST

MYSZ

Press Releases

TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Earnings

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

TFF Pharmaceuticals

TFF Pharmaceuticals (TFFP) Forecast

TFF Pharmaceuticals (NASDAQ:TFFP) Stock, Quote.Headers.trade-ideas